Navigation Links
bioLytical to Present Findings of Early HIV Detection
Date:7/7/2015

bioLytical Laboratories Inc. announced today that its abstract highlighting early HIV detection using INSTI HIV-1/HIV-2 Antibody Test was accepted for presentation at the 8th Annual International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver. The results will be presented Wednesday, July 22nd from 1:00 pm to 2:00pm Pacific Standard Time at the poster discussion on Novel Programmatic Approaches for Diagnostics.

bioLytical is pleased to be selected by IAS from many reputable abstract submissions and is looking forward to showcasing its new data at this internationally renowned conference. The conference will provide new insights into HIV disease development, prevention and treatment where approximately 6,000 delegates from across the globe will be in attendance.

The treatment as prevention (TasP) strategy established by Vancouver-based researcher, Dr. Julio Montaner, was first adopted by healthcare agencies in British Columbia (B.C.) and has shown impressive results that have rippled through the global HIV/AIDS community. By 2012, B.C.’s rate of new HIV diagnoses had decreased to their lowest point ever. With the recent adoption by the United Nations of the TasP strategy and the ambitious 90-90-90 target, Vancouver has become the perfect back drop to showcase innovations to the global scientific community.

“INSTI HIV-1/HIV-2 Antibody Test has been a recommended tool for HIV detection in all healthcare settings due to its quick, accurate results. Previously, studies have proven INSTI’s performance in early detection but bioLytical’s scientists have replicated and pinpointed this connection to IgM. The Company is delighted to have the opportunity to share these findings this month and looks forward to connecting with many key opinion leaders this year at the world-renowned IAS Conference.” said Rick Galli, Chief Technical Officer of bioLytical Laboratories.

In addition, the Company is equally pleased to announce its INSTI HIV-1/HIV-2 Antibody test will also be featured in two separate poster discussions at IAS 2015. The two poster discussion presentations (Abstract #WEPDD0106, Room 118-120 and Abstract #A-729-0097-02698, Room 121-122) titled “Sensitivity of a rapid point of care assay for early HIV antibody detection is enhanced by its affinity for HIV gp41 IgM antibodies” and "Reliability of rapid HIV-1/HIV-2 INSTI on plasma and capillary blood for diagnosis of non B subtypes and circulating recombinant forms of HIV-1 circulating in Gabon,” will be available on the bioLytical website at http://www.biolytical.com following the conference.

About bioLytical Laboratories
bioLytical Laboratories is a privately owned Canadian company engaged in the research, development and commercialization of rapid, point-of-care in vitro medical diagnostics using its proprietary INSTI™ technology platform. Today, the company markets and sells its signature INSTI™ HIV test and has a world-wide footprint of regulatory approvals including U.S. FDA approval, Health Canada approval and CE mark from European regulators. Their product provides a highly accurate HIV test result in as little as 60 seconds translating into a compelling value proposition for patients, healthcare professionals and public health organizations. For more information on bioLytical Laboratories, please visit http://www.biolytical.com.

Read the full story at http://www.prweb.com/releases/2015/07/prweb12833134.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. bioLytical Partners with Walgreens and Donates HIV Tests for National HIV Testing Day
2. bioLytical Laboratories Grants Exclusive Global License for 60 Second Ebola Assay
3. bioLyticals INSTI HIV Assay Receives FDA Approval for HIV-2
4. Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA
5. Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015
6. Pharnexts PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting
7. PDL BioPharma to Present at the Nasdaq 32nd Investor Program
8. Organovo Holdings, Inc. To Present at Cantor Fitzgerald Inaugural Healthcare Conference
9. Progyny to Present at the 2015 JMP Securities Life Science Conference
10. Vanda Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
11. Twist Bioscience To Present At The 2015 JMP Securities Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/9/2019)... ... 09, 2019 , ... The American Society of Gene & Cell Therapy ... including a new addition to the presidential line of succession, at the 22nd ... Society's leadership team for a three-year term (2019-2021). , All five incoming members of ...
(Date:4/4/2019)... ... April 03, 2019 , ... LeadingBiotech, an exclusive ... dialogue, today announces its Boston CEO conference to be held May 28-29, 2019 ... and opportunities with high-level panels and discussions from past, present and future change-makers. ...
(Date:3/23/2019)... ... March 22, 2019 , ... uBiome has awarded microbiome ... of researchers at Nnamdi Azikiwe University in Anambra State, Nigeria led by Dr. ... the Department of Medical Laboratory Sciences and Deputy Provost, College of Health Sciences. ...
(Date:3/19/2019)... ... March 19, 2019 , ... Konica ... today announced the formation of their inaugural Scientific Advisory Board. , ... that takes into account individual variability in genes, environment, and lifestyle to more ...
Breaking Biology Technology:
(Date:4/4/2019)... ... April 03, 2019 , ... R3 Stem ... at its nationwide Centers of Excellence. R3 wants patients to feel secure when ... To protect patients from Centers that use inferior regenerative biologics, protocols or amounts, ...
(Date:3/29/2019)... ... March 28, 2019 , ... In the wake ... programme entirely dedicated to Chinese biobanks was launched in July 2018, in an ... the Biobank Branch, China Medicinal Biotech Association (BBCMBA). The one-year pilot programme offered ...
(Date:3/27/2019)... ... 2019 , ... Evan Holden , a shareholder in the Atlanta ... at the National Academy of Sciences (NAS) Roundtable on Biomedical Engineering Materials Applications (BEMA), ... firm’s award-winning Pharmaceutical, Medical Device & Health Care Litigation Practice , addressed, “Medical ...
Breaking Biology News(10 mins):